Eqis Capital Management Has Decreased Its Silicon Motion Technology (SIMO) Position; ADMA BIOLOGICS Has 3 Sentiment

ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, makes, and intends to commercialize specialty plasma biologics for the treatment and prevention of immune deficiencies and infectious diseases. The company has market cap of $191.69 million. The Company’s lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical study for the treatment of primary immune deficiency disease. It currently has negative earnings. The firm also operates source plasma collection facilities in Norcross and Marietta, Georgia.

Eqis Capital Management Inc decreased Silicon Motion Technology (SIMO) stake by 85.5% reported in 2017Q3 SEC filing. Eqis Capital Management Inc sold 36,994 shares as Silicon Motion Technology (SIMO)’s stock rose 17.92%. The Eqis Capital Management Inc holds 6,272 shares with $301,000 value, down from 43,266 last quarter. Silicon Motion Technology now has $1.66B valuation. The stock increased 0.94% or $0.43 during the last trading session, reaching $46.36. About 458,116 shares traded. Silicon Motion Technology Corporation (NASDAQ:SIMO) has risen 21.46% since March 8, 2017 and is uptrending. It has outperformed by 4.76% the S&P500.

The stock increased 8.18% or $0.32 during the last trading session, reaching $4.23. About 181,948 shares traded or 44.10% up from the average. ADMA Biologics, Inc. (ADMA) has declined 37.56% since March 8, 2017 and is downtrending. It has underperformed by 54.26% the S&P500.

Aisling Capital Llc holds 1.83% of its portfolio in ADMA Biologics, Inc. for 3.61 million shares. Iguana Healthcare Management Llc owns 565,000 shares or 0.97% of their US portfolio. Moreover, Consonance Capital Management Lp has 0.43% invested in the company for 1.27 million shares. The New York-based Perceptive Advisors Llc has invested 0.08% in the stock. Prelude Capital Management Llc, a New York-based fund reported 39,000 shares.

Among 18 analysts covering Silicon Motion (NASDAQ:SIMO), 14 have Buy rating, 1 Sell and 3 Hold. Therefore 78% are positive. Silicon Motion has $68.75 highest and $19 lowest target. $51.84’s average target is 11.82% above currents $46.36 stock price. Silicon Motion had 41 analyst reports since July 28, 2015 according to SRatingsIntel. The firm has “Buy” rating by KeyBanc Capital Markets given on Wednesday, September 6. Susquehanna maintained the shares of SIMO in report on Wednesday, February 7 with “Hold” rating. The stock has “Buy” rating by Roth Capital on Tuesday, October 24. On Friday, January 29 the stock rating was maintained by Topeka Capital Markets with “Buy”. The stock of Silicon Motion Technology Corporation (NASDAQ:SIMO) earned “Buy” rating by Standpoint Research on Thursday, January 14. Topeka Capital Markets maintained Silicon Motion Technology Corporation (NASDAQ:SIMO) rating on Tuesday, July 28. Topeka Capital Markets has “Buy” rating and $34 target. The firm has “Sell” rating given on Tuesday, June 6 by Standpoint Research. The firm has “Buy” rating given on Thursday, December 7 by Summit Redstone Partners. On Friday, October 27 the stock rating was maintained by Northland Capital with “Buy”. Susquehanna initiated the shares of SIMO in report on Tuesday, September 8 with “Positive” rating.